BMRN at a glance
Biomarin Pharmaceutical Inc (BMRN, SEC CIK 1048477) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 6, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Biomarin Pharmaceutical Inc (BMRN) reported revenue of $3.2 billion (up 12.9% from FY2024) and net income of $348.9 million. Diluted EPS was $1.80.
- As of June 30, 2026, 37 institutional investment managers tracked by SignalX reported holding Biomarin Pharmaceutical Inc (BMRN) shares worth $4.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Davis George Eric on September 2, 2026 of 17,557 shares at $66.28 per share.
- In the last 90 days, BMRN insiders reported 0 open-market purchases ($0) and 1 open-market sale ($1.2M) on Form 4, a net sale of $1.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.2B
- +12.9% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$1.2M
- 13F holders
- 37 funds
- $4.7B · +2 vs prior quarter
- Latest 10-Q
- Aug 6, 2026
- Quarterly report
SignalX for BMRN
Don't miss the next BMRN filing
- Alerts as it files. A push when BMRN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BMRN, by share count.
- Ask anything. An AI agent that reads every BMRN filing and answers with sources.
BMRN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Friberg Gregory R | F | Sep 30, 2026 | 4,086 | $60.00 |
| Plenge Robert M | A | Sep 10, 2026 | 6,140 | - |
| Davis George Eric | Sell | Sep 2, 2026 | 17,557 | $66.28 |
| Dere Willard H | A | Jun 2, 2026 | 7,490 | - |
| Enyedy Mark J | A | Jun 2, 2026 | 7,490 | - |
| ANDERSON ELIZABETH M | A | Jun 2, 2026 | 7,490 | - |
| Walbert Timothy P | A | Jun 2, 2026 | 7,490 | - |
| CLARK IAN T | A | Jun 2, 2026 | 7,490 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.9B | $3.2B |
| Operating Income | - | $484.2M | $409.5M |
| Net Income | $167.6M | $426.9M | $348.9M |
| Op. Margin | - | 17.0% | 12.7% |
| Net Margin | - | 15.0% | 10.8% |
| Balance Sheet | |||
| Total Assets | $6.8B | $7.0B | $7.6B |
| Equity | - | $5.7B | $6.1B |
| ROE | - | 7.5% | 5.7% |
| Per Share | |||
| EPS | $0.87 | $2.21 | $1.80 |
| Cash Flow | |||
| Operating CF | - | $572.8M | $828.0M |
| CapEx | $96.7M | $85.4M | $103.0M |
Source: XBRL data in Biomarin Pharmaceutical Inc (BMRN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BMRN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 37 | $4.75B |
| Q1 2026 | 35 | $4.81B |
| Q4 2025 | 33 | $4.77B |
| Q3 2025 | 33 | $4.57B |
| Q2 2025 | 34 | $5.07B |
| Q1 2025 | 31 | $4.35B |
| Q4 2024 | 26 | $3.59B |
| Q3 2024 | 23 | $2.37B |
- FMR LLC (Fidelity)+1.26M (+35%)
- Goldman Sachs Group+822.4K (+217%)
- BlackRock+626.9K (+3%)
- Viking Global Investors+554.5K (+8%)
- State Street Corp+505.9K (+7%)
- Citadel Advisors LLC−3.39M (-75%)
- AQR Capital Management−1.98M (-26%)
- Millennium Management−938.5K (-31%)
- Renaissance Technologies LLC−573.0K (-56%)
- Bank of America Corp−273.8K (-29%)
- Blackstone Group+8.5K
- Marex Group plc+4.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 252 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BMRN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BMRN SEC filings: frequently asked questions
Are BMRN insiders buying or selling?
In the last 90 days, Biomarin Pharmaceutical Inc (BMRN) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $1.2 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BMRN stock?
As of June 30, 2026, the largest Biomarin Pharmaceutical Inc (BMRN) holders among the 13F filers tracked by SignalX were BlackRock ($1.2 billion), Vanguard Capital Management LLC ($500.3 million), Vanguard Portfolio Management LLC ($494.9 million), State Street Corp ($446.4 million), Viking Global Investors ($435.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BMRN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Biomarin Pharmaceutical Inc (BMRN) reported revenue of $3.2 billion (up 12.9% from FY2024) and net income of $348.9 million. Diluted EPS was $1.80. The figures come from the XBRL data in the 10-K.
What are the latest BMRN SEC filings?
Biomarin Pharmaceutical Inc (BMRN) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 6, 2026 and a Form 4 insider filing on October 1, 2026.
What is BMRN's SEC CIK number?
Biomarin Pharmaceutical Inc (BMRN)'s SEC Central Index Key (CIK) is 1048477. EDGAR lists every BMRN filing under that number.
Ask anything about BMRN
The research agent reads BMRN's filings, financials, insider trades and 13F holders, then answers with sources.